Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

BACKGROUND. Therapies targeting vascular endothelial growth factor (VEGF) are associated with hypertension, cardiotoxicity, and thromboembolic events. METHODS. All prospective phase I–III clinical trials published up to December 2008 of approved anti-VEGF therapies (bevacizumab, sunitinib, sorafenib...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vaklavas, Christos, Lenihan, Daniel, Kurzrock, Razelle, Tsimberidou, Apostolia Maria
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2010
Konular:
Cancer Biology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227935/
https://ncbi.nlm.nih.gov/pubmed/20139170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0252
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller